| 1. |
|
|
| 2. |
|
|
| 3. |
- Zuber, B, et al.
(författare)
-
An in vivo model for HIV resistance development
- 2001
-
Ingår i: AIDS research and human retroviruses. - : Mary Ann Liebert Inc. - 0889-2229 .- 1931-8405. ; 17:7, s. 631-635
-
Tidskriftsartikel (refereegranskat)
|
|
| 4. |
- Arteaga, H J, et al.
(författare)
-
Choosing CCR5 or Rev siRNA in HIV-1
- 2003
-
Ingår i: Nature Biotechnology. - : Springer Science and Business Media LLC. - 1087-0156 .- 1546-1696. ; 21:3, s. 230-231
-
Tidskriftsartikel (refereegranskat)
|
|
| 5. |
|
|
| 6. |
- Belshe, R, et al.
(författare)
-
Support for the RV144 HIV vaccine trial
- 2004
-
Ingår i: Science (New York, N.Y.). - : American Association for the Advancement of Science (AAAS). - 1095-9203 .- 0036-8075. ; 305:5681, s. 177-177
-
Tidskriftsartikel (övrigt vetenskapligt/konstnärligt)
|
|
| 7. |
|
|
| 8. |
|
|
| 9. |
|
|
| 10. |
|
|
| 11. |
|
|
| 12. |
- Hulstrom, AL, et al.
(författare)
-
Human natural killer cells in asymptomatic human immunodeficiency virus-1 infection
- 2000
-
Ingår i: Intervirology. - : S. Karger AG. - 0300-5526 .- 1423-0100. ; 43:4-6, s. 294-301
-
Tidskriftsartikel (refereegranskat)abstract
- <i>Objectives:</i> We evaluated whether DNA immunization with HIV-1 regulatory genes change natural killer (NK) effector cell activity. NK cells are the most important cells for the immediate host defense against virus-infected and tumor cells. We analyzed the NK activities of HIV-1-infected individuals against K562 cells (the classical assay) as well as against a CD4+ cell line with and without HIV-1 infection. CD4+ T lymphocytes are the main target cells for HIV-1 infection in vivo. Various proportions of the CD4+ T lymphocyte population carry the HIV-1 genome, produce virus and contribute to the systemic spread of HIV-1. <i>Methods:</i> CD4+ cell lines were established through HTLV-1 transformation which made the cells susceptible to NK lysis. NK activity was then tested in a <sup>51</sup>Cr release assay. <i>Results:</i> NK cells of asymptomatic HIV-infected individuals mediated considerable lytic activity against K562 cells as well as against the uninfected and HIV-1-infected CD4+ cell line, and so did the NK cells of HIV-1-infected patients on highly active antiretroviral treatment. <i>Conclusion:</i> DNA immunization with HIV-1-regulatory genes did not significantly change the NK effector cell activity.
|
|
| 13. |
- Isaguliants, MG, et al.
(författare)
-
DNA-encoding enzymatically active HIV-1 reverse transcriptase, but not the inactive mutant, confers resistance to experimental HIV-1 challenge
- 2000
-
Ingår i: Intervirology. - : S. Karger AG. - 0300-5526 .- 1423-0100. ; 43:4-6, s. 288-293
-
Tidskriftsartikel (refereegranskat)abstract
- The present study was undertaken to examine the immunogenicity of a single plasmid DNA representing the reverse transcriptase (RT) of HIV-1. Plasmids containing the enzymatically active RT as well as a mutated nonenzymatically active RT with nucleotide (nt)-binding motifs of YMDD and YMLL, respectively, were used to immunize mice. Both constructs induced similar good antibody and T cell responses, with a tendency towards antibody directed to peptides representing the active and mutated sites. Immunized mice were challenged with a murine pseudotype HIV-1/MuLV infected spleen cells. Seven out of 10 mice immunized with RT had no recoverable HIV-1, while 10 individuals immunized with the RT mutant and all the 18 controls had high levels of recoverable HIV-1. This indicates that mutation of RT reduces the desired immunogenicity.
|
|
| 14. |
|
|
| 15. |
- Lundholm, P, et al.
(författare)
-
DNA mucosal HIV vaccine in humans
- 2002
-
Ingår i: Virus research. - : Elsevier BV. - 0168-1702. ; 82:1-2, s. 141-145
-
Tidskriftsartikel (refereegranskat)
|
|
| 16. |
- Makitalo, B, et al.
(författare)
-
Enhanced cellular immunity and systemic control of SHIV infection by combined parenteral and mucosal administration of a DNA prime MVA boost vaccine regimen
- 2004
-
Ingår i: The Journal of general virology. - : Microbiology Society. - 0022-1317 .- 1465-2099. ; 85:Pt 8, s. 2407-2419
-
Tidskriftsartikel (refereegranskat)abstract
- The immunogenicity and protective efficacy of a DNA and recombinant modified vaccinia Ankara (MVA) vaccine administered by two different routes were investigated. DNA expressing HIV-1 IIIB env, gag, RT, rev, tat and nef, and MVA expressing HIV-1 IIIB nef, tat and rev and simian immunodeficiency virus (SIV) macJ5 gag/pol and vaccinia HIV-1 env, were used as immunogens. Four cynomolgus macaques received DNA intramuscularly (i.m.) at month 0 and intrarectally (i.r.) and intra-orally (i.o.) at 2 months, followed by MVA i.m. at 4 months and i.r. and i.o. at 8 months. Another group of four monkeys received the same immunogens but only i.m.. Overall, stronger cellular immune responses measured by ELISPOT and T-cell proliferation assay were detected in the group primed i.m. and boosted mucosally. Following homologous intravenous simian-human immunodeficiency virus (SHIV) challenge, one of eight vaccinated animals was completely protected. This monkey, immunized i.m. and i.r.+i.o., exhibited the highest levels of HIV Env, Nef and Tat antibodies, high HIV Tat cytotoxic T-lymphocyte activity and T-lymphocyte proliferative responses to HIV Env. Four weeks post-challenge none of the monkeys immunized i.m. and i.r.+i.o., and only two out of four animals immunized i.m., demonstrated detectable plasma viral RNA levels. In contrast, all eight control animals had demonstrable plasma viral RNA levels 4 weeks post-challenge. Thus, stronger cellular immune responses and reduction of challenge virus burden were demonstrated in animals immunized i.m. as well as mucosally, compared with animals immunized i.m. only. The breadth and magnitude of the induced immune responses correlated with protective efficacy.
|
|
| 17. |
|
|
| 18. |
|
|
| 19. |
|
|
| 20. |
|
|
| 21. |
|
|
| 22. |
|
|
| 23. |
|
|
| 24. |
|
|
| 25. |
|
|
